Fireside Chat: Inside the $1.5B Deal – Building a Partnership with Global Scale

Session details:

Unnatural Products' recent collaboration with argenx made headlines not just for its size, but for its ambition: leveraging macrocyclic peptide technology to create first-in-class oral therapeutics. In this candid conversation, Co-Founder Cameron Pye takes us behind the scenes of the $1.5 billion multi-target deal to explore how it came together and what it signals for the future of modality-driven partnerships.

• Gain insight into how Unnatural Products positioned its platform to address pharma’s need for oral alternatives to antibody therapies
• Learn how the teams aligned on strategy, value, and risk-sharing in a complex, multi-asset deal
• Hear how innovative biotech companies are navigating negotiations with global partners in a more cautious, ROI-focused BD environment